Innovative Eyewear, Inc.

Innovative Eyewear, Inc. develops and sells smart eyeglasses and sunglasses. The company's flagship product is Lucyd Lyte glasses that enable the wearer to listen to music, take and make calls, and use voice assistants to perform various smartphone tasks hands-free. It also offers Vyrb, a social media application that enables the user to receive and send posts through Lucyd Lyte smart glasses with voice. The company sells its products through various e-commerce and retail distribution channels. Innovative Eyewear, Inc. has a partnership with Lucyd. The company was founded in 2019 and is headquartered in North Miami, Florida. Innovative Eyewear, Inc. operates as a subsidiary of Lucyd Ltd.

Innovative Eyewear, Inc. trades as LUCY on NASDAQ. The company is classified in Healthcare / Medical - Instruments & Supplies and reports in USD.

The current profile places the business in Medical - Instruments & Supplies. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $2.66M of revenue and -$7.59M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Innovative Eyewear, Inc. can be compared against peers such as Aprea Therapeutics, Inc., BioCardia, Inc., Biomerica, Inc., Creative Medical Technology Holdings, Inc., Check-Cap Ltd., Kiora Pharmaceuticals, Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $3.62M, beta of 2.65, and return on equity of -83.7%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

LUCY currently shows total debt of $0 and beta of 2.65. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

Recent filings to review: 10-Q (2026-05-14 00:00:00), SC 13G/A (2026-05-13 00:00:00), 10-K (2026-03-25 00:00:00), SC 13G/A (2026-02-13 00:00:00).

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.lucyd.co

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.